tirzepatide cardiovascular outcome Real-World Outcomes of Obesity Treatment With Versus Semaglutide in Non-Diabetic Adults In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF Comparative Cardiovascular Pharmacovigilance of Semaglutide

Long-term use of tirzepatide may extend anti-inflammatory benefits by maintaining reduced body weight, improving insulin sensitivity, and supporting sustained metabolic health

The Phase 2 trial used 4-week intervals between increases, and groups that followed dose escalation had better tolerability than those started at fixed higher doses

Always so friendly and welcoming that you never feel uncomfortable about talking about your weight problems to them

According to a systematic review by Cochrane, semaglutide produces clinically significant weight loss compared to placebo , with most side effects being mild to moderate in severity